PMID- 22180097
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20211021
IS  - 1574-4647 (Electronic)
IS  - 0161-9152 (Print)
IS  - 0161-9152 (Linking)
VI  - 34
IP  - 5
DP  - 2012 Oct
TI  - Improving immunity in the elderly: current and future lessons from nonhuman 
      primate models.
PG  - 1157-68
AB  - The immune system must overcome daily challenges from pathogens to protect the 
      body from infection. The success of the immune response to infection relies on 
      the ability to sense and evaluate microbial threats and organize their 
      elimination, while limiting damage to host tissues. This delicate balance is 
      achieved through coordinated action of the innate and adaptive arms of the immune 
      system. Aging results in several structural and functional changes in the immune 
      system, often described under the umbrella term "immune senescence". Age-related 
      changes affect both the innate and adaptive arms of the immune system and are 
      believed to result in increased susceptibility and severity of infectious 
      diseases, which is further exacerbated by reduced vaccine efficacy in the 
      elderly. Therefore, multiple strategies to improve immune function in the aged 
      are being investigated. Traditionally, studies on immune senescence are conducted 
      using inbred specific pathogen free (SPF) rodents. This animal model has provided 
      invaluable insight into the mechanisms of aging. However, the limited genetic 
      heterogeneity and the SPF status of this model restrict the successful transfer 
      of immunological discoveries between murine models and the clinical setting. More 
      recently, nonhuman primates (NHPs) have emerged as a leading translational model 
      to investigate immune senescence and to test interventions aimed at 
      delaying/reversing age-related changes in immune function. In this article, we 
      review and summarize advances in immuno-restorative approaches investigated in 
      the NHP model system and discuss where the NHP model can support the development 
      of novel therapeutics.
FAU - Meyer, Christine
AU  - Meyer C
AD  - Vaccine and Gene Therapy Institute, Oregon Health and Science University, 
      Beaverton, OR, USA.
FAU - Kerns, Amelia
AU  - Kerns A
FAU - Haberthur, Kristen
AU  - Haberthur K
FAU - Messaoudi, Ilhem
AU  - Messaoudi I
LA  - eng
GR  - R01 AG037042-03/AG/NIA NIH HHS/United States
GR  - P51 RR000163/RR/NCRR NIH HHS/United States
GR  - RR00163/RR/NCRR NIH HHS/United States
GR  - R01 AG037042/AG/NIA NIH HHS/United States
GR  - K01 RR000163/RR/NCRR NIH HHS/United States
GR  - AG 037042/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111220
PL  - Netherlands
TA  - Age (Dordr)
JT  - Age (Dordrecht, Netherlands)
JID - 101250497
SB  - IM
MH  - *Adaptation, Physiological
MH  - Aging/*immunology
MH  - Animals
MH  - Disease Models, Animal
MH  - Immune System/*physiology
MH  - Infections/*immunology
MH  - Primates
PMC - PMC3448983
EDAT- 2011/12/20 06:00
MHDA- 2013/03/13 06:00
PMCR- 2013/10/01
CRDT- 2011/12/20 06:00
PHST- 2011/04/07 00:00 [received]
PHST- 2011/12/01 00:00 [accepted]
PHST- 2011/12/20 06:00 [entrez]
PHST- 2011/12/20 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - 9353 [pii]
AID - 10.1007/s11357-011-9353-y [doi]
PST - ppublish
SO  - Age (Dordr). 2012 Oct;34(5):1157-68. doi: 10.1007/s11357-011-9353-y. Epub 2011 
      Dec 20.